Here, we systematically examined proteomic and transcriptomic changes in patient-derived lymphoblasts and CRISPR/Cas9–engineered HeLa cells carrying ALS/FTD UBQLN2 mutations. The gene discussed is UBQLN2; the disease is amyotrophic lateral sclerosis.